[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574860":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":62,"centralContacts":65,"locations":73,"responsibleParty":179,"collaborators":11,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":11,"eligibilityCriteria":187,"healthyVolunteers":183,"sex":188,"minAge":189,"maxAge":11,"enrollmentInfo":190,"targetDuration":11,"studyType":193,"phases":194,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,18,22,26,29,32,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1A: BMS-986488 Monotherapy","EXPERIMENTAL",null,[13],"Drug: BMS-986488",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 1B: BMS-986488 + Adagrasib",[13,17],"Drug: Adagrasib",{"label":19,"type":10,"description":11,"interventionNames":20},"Part 1C: BMS-986488 + Adagrasib + Cetuximab",[13,17,21],"Drug: Cetuximab",{"label":23,"type":10,"description":11,"interventionNames":24},"Part 1D: BMS-986488 + Nivolumab",[13,25],"Drug: Nivolumab",{"label":27,"type":10,"description":11,"interventionNames":28},"Part 2A: BMS-986488 Monotherapy",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Part 2B: BMS-986488 + Adagrasib",[13,17],{"label":33,"type":10,"description":11,"interventionNames":34},"Part 2C: BMS-986488 + Adagrasib + Cetuximab",[13,17,21],{"label":36,"type":10,"description":11,"interventionNames":37},"Part 2D: BMS-986488 + Nivolumab",[13,25],[39,44,51,56],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"DRUG","BMS-986488","Specified dose on specified days",[9,15,19,23,27,30,33,36],{"type":40,"name":45,"description":42,"armGroupLabels":46,"otherNames":47},"Adagrasib",[15,19,30,33],[48,49,50],"KRAZATI","BMS-986503","MRTX849",{"type":40,"name":52,"description":42,"armGroupLabels":53,"otherNames":54},"Cetuximab",[19,33],[55],"ERBITUX",{"type":40,"name":57,"description":42,"armGroupLabels":58,"otherNames":59},"Nivolumab",[23,36],[60,61],"OPDIVO","BMS-936558",[63],{"name":5,"affiliation":5,"role":64},"STUDY_DIRECTOR",[66,71],{"name":67,"role":68,"phone":69,"phoneExt":11,"email":70},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":72,"role":68,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[74,92,103,117,128,140,152,166],{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"John Theurer Cancer Center at Hackensack University Medical Center","RECRUITING","Hackensack","New Jersey","07601","United States","US",{"type":83,"coordinates":84},"Point",[85,86],-74.04347,40.88593,{"lat":86,"lon":85},[89],{"name":90,"role":68,"phone":91,"phoneExt":11,"email":11},"Martin Gutierrez, Site 0021","551-996-5863",{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":80,"countryCode":81,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"Local Institution - 0020","ACTIVE_NOT_RECRUITING","Allentown","Pennsylvania","18103",{"type":83,"coordinates":99},[100,101],-75.49018,40.60843,{"lat":101,"lon":100},{"facility":104,"status":76,"city":105,"state":106,"zip":107,"country":80,"countryCode":81,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"The West Clinic, PLLC dba West Cancer Center","Germantown","Tennessee","38138",{"type":83,"coordinates":109},[110,111],-89.81009,35.08676,{"lat":111,"lon":110},[114],{"name":115,"role":68,"phone":116,"phoneExt":11,"email":11},"Daniel Vaena, Site 0024","901-598-1454",{"facility":118,"status":119,"city":120,"state":121,"zip":122,"country":80,"countryCode":81,"cosmosGeoPoint":123,"geoPoint":127,"contacts":11},"Local Institution - 0025","WITHDRAWN","Dallas","Texas","75390",{"type":83,"coordinates":124},[125,126],-96.80667,32.78306,{"lat":126,"lon":125},{"facility":129,"status":94,"city":130,"state":131,"zip":132,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":11},"Local Institution - 0031","Brisbane","Queensland","4029","Australia","AU",{"type":83,"coordinates":136},[137,138],153.02809,-27.46794,{"lat":138,"lon":137},{"facility":141,"status":94,"city":142,"state":143,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":151,"contacts":11},"Local Institution - 0032","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":83,"coordinates":148},[149,150],-123.11934,49.24966,{"lat":150,"lon":149},{"facility":153,"status":154,"city":155,"state":156,"zip":157,"country":145,"countryCode":146,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Local Institution - 0015","NOT_YET_RECRUITING","Montreal","Quebec","H2X 0A9",{"type":83,"coordinates":159},[160,161],-73.58781,45.50884,{"lat":161,"lon":160},[164],{"name":165,"role":68,"phone":11,"phoneExt":11,"email":11},"Site 0015",{"facility":167,"status":76,"city":168,"state":156,"zip":169,"country":145,"countryCode":146,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus","Québec","G1J 1Z4",{"type":83,"coordinates":171},[172,173],-71.21454,46.81228,{"lat":173,"lon":172},[176],{"name":177,"role":68,"phone":178,"phoneExt":11,"email":11},"Antoine Morin Coulombe, Site 0016","4185254444",{"type":180,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100574860","phase-1-a-study-of-bms-986488-as-monotherapy-and-combination-therapy-in-participants-with-advanced-malignant-tumors-100574860",false,"NCT06764771","A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","A Phase 1\u002F1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.\n* Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).\n* Parts 2A, 1D, 2D: ccRCC.\n\n  i) Part 1B: solid tumors with KRAS G12C mutation.\n\nii) Part 2B: NSCLC with KRAS G12C mutation.\n\niii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.\n\n* Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.\n* Participants must have measurable disease per RECIST v1.1.\n\nExclusion Criteria:\n\n* Untreated central nervous system (CNS) metastases.\n* Leptomeningeal metastasis (carcinomatous meningitis).\n* Impaired cardiac function or clinically significant cardiac disease.\n* For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.\n\n  i) History of pneumonitis or interstitial lung disease (ILD).\n\nii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).\n\n\\- Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":191,"type":192},437,"ESTIMATED","INTERVENTIONAL",[195],"PHASE1","This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.",[198],"Advanced Malignant Tumors",[200,201,202,203,204,205,206,207,208,209],"Colorectal Cancer","CRC","Renal Cell Carcinoma","RCC","Non-Small Cell Lung Cancer","NSCLC","Cancer","Oncology","Phase 1","Solid Tumor","2026-07-01",{"date":212,"type":213},"2026-07-02","ACTUAL",{"date":215,"type":213},"2025-03-25",{"date":217,"type":192},"2027-10-15",{"name":5,"class":6},8]